356547-40-5Relevant academic research and scientific papers
Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D2/D3Receptor Bitopic Ligands
Battiti, Francisco O.,Boateng, Comfort A.,Bonifazi, Alessandro,Cao, Jianjing,Chen, Li,Chitsazi, Rezvan,Lee, Kuo Hao,Newman, Amy Hauck,Ravi, Saiprasad,Shaik, Anver Basha,Shi, Lei
, p. 15313 - 15333 (2021/11/01)
The crystal structure of the dopamine D3 receptor (D3R) in complex with eticlopride inspired the design of bitopic ligands that explored (1) N-alkylation of the eticlopride's pyrrolidine ring, (2) shifting of the position of the pyrrolidine nitrogen, (3)
Capped dipeptide phenethylamide inhibitors of the HCV NS3 protease
Nizi, Emanuela,Koch, Uwe,Ontoria, Jesus M.,Marchetti, Antonella,Narjes, Frank,Malancona, Savina,Matassa, Victor G.,Gardelli, Cristina
, p. 2151 - 2154 (2007/10/03)
The N-terminal aminoacid of phenethylamide tripeptide inhibitors of the hepatitis C virus NS3 protease can be replaced with an α-hydroxy acid to obtain more 'drug like' inhibitors with low micromolar activity. The preferred S-configuration of the capping
O-benzyl hydroxyproline as a bioisostere for Phe-Pro: Novel dipeptide thrombin inhibitors
Klein, Scott I.,Dener, Jeffrey M.,Molino, Bruce F.,Gardner, Charles J.,D'Alisa, Rose,Dunwiddie, Christopher T.,Kasiewski, Charles,Leadley, Robert J.
, p. 2225 - 2230 (2007/10/03)
A series of analogs were prepared based on the known thrombin inhibitor PPACK, in which the D-Phe-Pro dipeptide has been replaced by trans-4-O-benzyl hydroxyproline. One of these analogs is a more potent inhibitor of thrombin, and is more selective, than PPACK itself.
